Wednesday, July 16, 2025 7/16/2025

Novel immunotherapy against MOG antibody disease

Award Number: R44TR005293
ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/15/2022
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

Novel immunotherapy against MOG antibody disease - PROJECT SUMMARY/ABSTRACT Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOGAD) is a rare disease characterized as a neurological, inflammatory, demyelinating disorder of the central nervous system. The symptoms of MOGAD include vision loss, symptoms associated with damage to the spinal cord, as well as seizures. While the current standard of care against MOGAD includes steroids and immunosuppressants, they are associated with systemic immunosuppression with complications and frequent debilitating relapses. Thus, there is an urgent need for new targeted treatment options for MOGAD patients. As MOG is the sole target antigen in MOGAD patients, MOG is an attractive target. Here, we propose to develop a novel nanoparticle platform for the treatment of MOGAD. Toward this goal, we have developed synthetic high-density lipoprotein NanoDiscs for efficient delivery of antigen peptides to lymph nodes. Our preliminary data shows that NanoDiscs induce robust antigen-specific immune tolerance and disease modification in murine models of experimental autoimmune encephalomyelitis (EAE) and another autoimmune disorder, type 1 diabetes (T1D). Based on our compelling proof-of-concept data, here we propose to further develop NanoDiscs for the treatment of MOGAD.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $988,943 )
2025	2025	EVOQ THERAPEUTICS, INC.	1600 HURON PARKWAY	ANN ARBOR	MI	48109	WASHTENAW	USA	National Center for Advancing Translational Sciences	000	3	6/18/2025	NON-COMPETING CONTINUATION	$988,943
														Subtotal = $988,943

Issue Date FY: 2024 ( Subtotal = $1,000,000 )
2024	2024	EVOQ THERAPEUTICS, INC.	1600 HURON PARKWAY	ANN ARBOR	MI	48109	WASHTENAW	USA	National Center for Advancing Translational Sciences	000	2	7/11/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$1,000,000
														Subtotal = $1,000,000

Grand Total All Awards = $1,988,943

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Novel immunotherapy against MOG antibody disease

Award Number: R44TR005293

ORGANIZATION: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/15/2022

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer